Guided Therapeutics

Guided Therapeutics Current Liabilities

The Current Liabilities of Guided Therapeutics (GTHP) as of Oct 18, 2026 is 2.48 M USD. In the previous year, Current Liabilities was 3.67 M USD — a change of -32.32% (lower).

Current Liabilities

2.48 MUSD

YoY

-32.32%

Last updated:

Current Liabilities of Guided Therapeutics is 2025 2.48 M USD. Current Liabilities of Guided Therapeutics was 2024 3.67 M USD. It decreases by -32.32% lower compared to the previous year.

The Guided Therapeutics Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
9.83 M USD
Jan 1, 2019
10.15 M USD
Jan 1, 2020
7.79 M USD
Jan 1, 2021
5.23 M USD
Jan 1, 2022
3.85 M USD
Jan 1, 2023
2.90 M USD
Jan 1, 2024
3.67 M USD
Jan 1, 2025
2.48 M USD
The Guided Therapeutics Current Liabilities history
YEARCurrent LiabilitiesYoY
2.48 MUSD-32.32%
3.67 MUSD+26.77%
2.90 MUSD-24.71%
3.85 MUSD-26.43%
5.23 MUSD-32.91%
7.79 MUSD-23.27%
10.15 MUSD+3.23%
9.83 MUSD-6.84%
10.56 MUSD+13.13%
9.33 MUSD+70.57%
5.47 MUSD+18.91%
4.60 MUSD+159.89%
1.77 MUSD-24.68%
2.35 MUSD-13.92%
2.73 MUSD-1.80%
2.78 MUSD-78.21%
12.76 MUSD+49.77%
8.52 MUSD+124.80%
3.79 MUSD-64.41%
10.65 MUSD+46.69%
7.26 MUSD+16.72%
6.22 MUSD+71.35%
3.63 MUSD+87.11%
1.94 MUSD-12.22%
2.21 MUSD-3.07%
2.28 MUSD+44.30%
1.58 MUSD+88.10%
840,000.00USD-34.38%
1.28 MUSD+34.74%
950,000.00USD+18.75%
800,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Guided Therapeutics Stock analysis

What does Guided Therapeutics do? Guided Therapeutics Inc, with ticker GTHP and ISIN US40171F5017, is a health care company headquartered in Norcross, Georgia. The company has 6 employees and went public on July 1, 1997. Guided Therapeutics focuses on developing medical devices, particularly utilizing biophotonic technology for cancer detection. The company's primary product is the LuViva Advanced Cervical Scan, a non-invasive device designed to detect cervical cancer and precancers. The LuViva device scans the cervix with light and analyzes the reflected and fluorescent light to provide results at the point of care. It serves as an alternative to conventional cervical cancer screening methods, targeting two main applications: as a screening tool and as a triage method for traditional screening processes. The company develops prototypes and conducts limited clinical studies using its biophotonic technology, which is central to its approach for detecting esophageal cancer. Guided Therapeutics operates within the health care sector and industry, with its website at https://www.guidedinc.com/. The company's current operational focus is on the development and marketing of the LuViva device, though it has also explored applications in esophageal cancer detection through biophotonic technology. Guided Therapeutics has a small workforce of six full-time employees, reflecting its current scale of operations. Guided Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guided Therapeutics stock

Current Liabilities of Guided Therapeutics is 2.48 M USD in 2025.

Current Liabilities of Guided Therapeutics changed from 3.67 M USD to 2.48 M USD, representing a -32.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Guided Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Guided Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Guided Therapeutics

All Key Metrics — Guided Therapeutics